Insmed (INSM) Net Cash Flow Growth (1y) (2011 - 2026)
Insmed (INSM) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-14,223.53% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Insmed |
19.79 Bn |
18.57 Bn |
258.54 Mn |
147.35% |
| Date | Value |
|---|
| Mar 31, 2026 |
147.35% |
| Dec 31, 2025 |
84.76% |
| Sep 30, 2025 |
-20.50% |
| Jun 30, 2025 |
35.03% |
| Mar 31, 2025 |
-233.57% |
| Dec 31, 2024 |
1,752.77% |
| Sep 30, 2024 |
-515.29% |
| Jun 30, 2024 |
284.83% |
| Mar 31, 2024 |
208.76% |
| Dec 31, 2023 |
-100.87% |
| Sep 30, 2023 |
-3,783.94% |
| Jun 30, 2023 |
-256.57% |
| Mar 31, 2023 |
47.48% |
| Dec 31, 2022 |
609.52% |
| Sep 30, 2022 |
95.95% |
| Jun 30, 2022 |
-119.07% |
| Mar 31, 2022 |
-63.01% |
| Dec 31, 2021 |
-130.28% |
| Sep 30, 2021 |
-52.51% |
| Jun 30, 2021 |
143.60% |
